$IMMU - Immunomedics Reported Improved Progression
Post# of 51
Posted On: 11/09/2015 12:25:29 PM
$IMMU - Immunomedics Reported Improved Progression-Free Survival Results With Sacituzumab Govitecan in Triple-Negative Breast Cancer
Read More: http://investorshangout.com/post/view?id=3324...z3r13vs5YR
Quote:
"Patients in this late-stage setting usually have a median PFS of three to four months when treated with other agents," stated Aditya Bardia, MD, MPH, Assistant Professor of Medicine at Harvard Medical School, Attending Physician at the Massachusetts General Hospital Cancer Center in Boston, and an investigator in this trial. "Sacituzumab govitecan is a promising agent that offers hope for these patients with poor prognosis," Dr. Bardia added.
Read More: http://investorshangout.com/post/view?id=3324...z3r13vs5YR
(0)
(0)Immunomedics Inc. (IMMU) Stock Research Links
Scroll down for more posts ▼